• Age >=18 years
• Foveal center-involved macular edema secondary to BRVO
• OCT central subfield thickness >250 microns on two OCT measurements
• BCVA using ETDRS charts of 20/50 to 20/400 (Snellen equivalent) in the study eye

We are looking for people 18 years of age or older who are available for 12 clinic visits over a 1 year period of time.  Qualified study participants will be provided with the following at no charge:

• Study-related eye examination
• Study drug

Diabetic Eyes Studies

RISE STUDY

Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD &  Mukesh B. Suthar, MD
(Please add a link to their Bios)

This study is evaluating the use of Ranibizumab injection for the treatment of patients with CSME secondary to diabetes mellitus.

Major eligibility include:

• Age > 18 years
• Diabetes mellitus (Type 1 or 2)
• OCT central subfield thickness >275mm
• Know duration of DME < 2 years
• BCVA using ETDRS charts of 20/40 to 20/320 (Snellen equivalent )

Clinic visits will take place approximately once per month for 36 months.

http://www.nie.nih.gov/health/diabetic/retinopathy.asp

As part of the Diabetic Retinopathy Clinical Research Network, we are actively enrolling patients in the following DRCR.NET studies:

DRCR I:

Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema

Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD &  Mukesh B. Suthar, MD

Study Objective: To evaluate safety and efficacy of the following in eyes with center-involved DME

• Intravitreal Ranibizumab in combination with focal laser
• Intravitreal Ranibizumab alone
• Intravitreal Triamcinolone in combination with focal lase

• Age >=18 years
• Type 1 or type 2 diabetes
• Center involved DME responsible for visual acuity of 20/32 or worse
• OCT central subfield thickness > 250 microns
• Subjects may have one or two study eyes

DRCR J:

Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD &  Mukesh B. Suthar, MD

Study Objective:

To determine whether intravitreal injection of an anti-VEGF drug or an intravitreal injection of a corticosteroid can reduce the risk of visual acuity impairment that can occur following PRP and increase the chances of at least short-term visual acuity improvement in eyes with evidence of center-involved macular edema that are undergoing PRP for severe NPDR or PDR.

Major Eligibility Criteria:

• Age >=18 years
• Type 1 or type 2 diabetes
• Study eye with severe nonproliferative or proliferative diabetic retinopathy for which the investigator intends to perform full scatter photocoagulation
• Diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns)

Sample size 381 eyes (one per subject)

Regeneron Study (VEGF Trap – Reg 0605)

Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD &  Mukesh B. Suthar, MD

http://clinicaltrials.gov/ct2/show/NCT00509795term=View+1&rank=1&AddInterest=1027

Age-Related Macular Degeneration (AMD) is a leading cause of adult blindness in the developed world.  Severe visual loss from AMD is caused by a combination of retinal edema and neovascular proliferation.  Vascular Endothelial Growth Factor (VEGF), a protein growth factor that both stimulates angiogenesis and increases vascular permeability, is a major pathogenic factor in AMD.  Counteracting these effects of VEGF provide significant therapeutic benefit to subjects suffering from this disorder.

This study assesses the efficacy of intravitreal (ITV) administered VEGF Trap compared to ranibizumab in a non-inferiority paradigm in preventing moderate vision loss in subjects with all subtypes of neovascular AMD.

Major eligibility criteria:

• Age >=18 years.
• Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye.
• ETDRS best-corrected visual acuity of: 20/40 to 20/320 (letter score of 73 to 25) in the study eye.

Through participation patients can expect to receive:

• No cost study drug at one of two study drug doses
• No cost study related eye exam

For more information please contact:

• Cara Davidson -(909) 558-2168
• Kara Rollins - (909) 558-2170
• Gisela Santiago - (909) 558-2169